SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports Q2 2025 results; CyPath Lung revenues up 62% year-over-year in first six months of 2025
Related Questions
How will the 62% YoY increase in CyPath Lung revenues affect bioAffinity's overall earnings guidance for 2025?
How does bioAffinity's Q2 revenue growth compare to its peers in the molecular diagnostics space?
What are the margins on the CyPath Lung product line, and are they improving?
Did the company provide any guidance on future revenue growth or profitability targets?
What is the contribution of CyPath Lung to total Q2 revenue compared to previous quarters?
Are there any updates on the commercial rollout or market adoption rates of CyPath Lung tests?
Is there any information on upcoming product launches or pipeline developments that could impact valuation?
How did operating expenses and cash burn change in Q2 relative to the same period last year?
What is the analyst sentiment and target price adjustments following this earnings release?
Are there any regulatory updates or reimbursements that could further accelerate CyPath Lung adoption?